Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 215

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 215
---
ch Ltd, which acquired its base nanoparticle
technology through an assignment of worldwide commercialization rights and joint ownership of patent rights from Consejo Superior de Investigaciones
Cientificas, or CSIC, in Madrid, Spain. Midatech Ltd was a research and development focused biotech company which subsequently advanced
and developed this gold nanoparticle drug delivery platform technology to enhance the delivery of medicines for major therapeutic indications
where clinical therapeutic options are limited, with a particular focus on certain cancers, such as liver and brain cancer.

To better be able to continue
the commercial development of the research and development programs of Midatech Ltd, Midatech Pharma PLC was incorporated on September
12, 2014 under the laws of England and Wales, to be the public holding company of Midatech Ltd and Midatech Pharma (Wales) Limited under
registered number 09216368. On December 8, 2014, we completed our initial public offering of our Ordinary Shares in the United Kingdom.

On March 31, 2020 we announced
that, in the context of prevailing conditions in the capital markets, we did not expect to be able to raise capital to fund the continued
development of MTD201, including scale-up of MTD201 manufacturing at our Bilbao facilities. We determined to conduct a strategic review
of our operations, cease further investment in MTD201 and close our operations in Bilbao, Spain, including making all our employees in
Bilbao redundant.

On April 20, 2020, we announced
an update to the strategic review of operations including the appointment of Noble Capital Markets, Inc. to advise us on options for extracting
value from our technologies, including partnering our clinical stage assets, partnering existing and upcoming proof of concept formulations,
partnering or selling one or more of our technologies or selling the entire Company.

On January 26, 2021, we announced,
among other things, that the strategic review had completed and that we were now focused on executing our realigned strategy of deploying
our technologies to develop more early stage products and seeking licensing partners at proof of concept stage.

On
March 24, 2023, we held a general meeting where our shareholders approved, among other things, a change of our name to “Biodexa
Pharmaceuticals PLC” and the cancellation of admission of our Ordinary Shares from trading on AIM with effect from April 26, 2023.
Additionally, the names of Midatech Ltd and